Renaissance Technologies LLC increased its stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 13.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,724,800 shares of the medical research company’s stock after purchasing an additional 209,500 shares during the quarter. Renaissance Technologies LLC’s holdings in Charles River Laboratories Intl. were worth $232,055,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Rhumbline Advisers increased its stake in Charles River Laboratories Intl. by 4.7% in the second quarter. Rhumbline Advisers now owns 106,963 shares of the medical research company’s stock valued at $12,008,000 after purchasing an additional 4,842 shares during the period. Mackay Shields LLC increased its stake in Charles River Laboratories Intl. by 272.4% in the second quarter. Mackay Shields LLC now owns 46,182 shares of the medical research company’s stock valued at $5,184,000 after purchasing an additional 33,781 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Charles River Laboratories Intl. in the second quarter valued at $460,000. Dynamic Technology Lab Private Ltd acquired a new position in Charles River Laboratories Intl. in the second quarter valued at $212,000. Finally, Cadence Capital Management LLC increased its stake in Charles River Laboratories Intl. by 7.1% in the third quarter. Cadence Capital Management LLC now owns 13,142 shares of the medical research company’s stock valued at $1,768,000 after purchasing an additional 873 shares during the period. Hedge funds and other institutional investors own 96.20% of the company’s stock.

A number of research analysts have commented on CRL shares. Robert W. Baird lifted their price objective on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Raymond James lifted their price objective on shares of Charles River Laboratories Intl. from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 8th. Credit Suisse Group dropped their price objective on shares of Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 21st. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th. Finally, Royal Bank of Canada set a $147.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a research note on Wednesday, November 7th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $132.06.

In related news, insider David P. Johst sold 23,356 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the sale, the insider now owns 219,849 shares of the company’s stock, valued at $29,899,464. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Ross Smith sold 1,866 shares of the business’s stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $134.49, for a total transaction of $250,958.34. Following the sale, the insider now directly owns 12,341 shares in the company, valued at approximately $1,659,741.09. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

Shares of NYSE:CRL opened at $130.92 on Thursday. The stock has a market capitalization of $6.43 billion, a PE ratio of 24.84, a PEG ratio of 1.88 and a beta of 0.74. The company has a current ratio of 1.55, a quick ratio of 1.32 and a debt-to-equity ratio of 1.32. Charles River Laboratories Intl. Inc has a fifty-two week low of $96.70 and a fifty-two week high of $139.72.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.15. The business had revenue of $585.30 million for the quarter, compared to the consensus estimate of $567.58 million. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.08%. The business’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.30 earnings per share. On average, equities analysts predict that Charles River Laboratories Intl. Inc will post 5.92 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/charles-river-laboratories-intl-inc-crl-shares-bought-by-renaissance-technologies-llc/2665040.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Diversification

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.